Opioid Prescriptions by Surgeons for Post-Op Pain Relief Decline, but Progress Has Slowed

PainRelief.com Interview with:
Kao-Ping Chua, MD, PhD
Susan B. Meister Child Health Evaluation and Research Center
Department of Pediatrics, University of Michigan Medical School
Ann Arbor MI 48109

Dr. Kao-Ping Chua
Dr. Kao-Ping Chua

PainRelief.com: What is the background for this study?

Response: Surgery is one of the most common reasons for opioid prescribing. Ensuring the appropriateness of opioid prescribing by surgeons is important, as prescriptions that exceed patient need result in leftover pills that can be a source for misuse or diversion. Although there have been numerous recent policy and clinical efforts to improve opioid prescribing by surgeons, recent national data on this prescribing are unavailable.

In this study, we analyzed a comprehensive prescription dispensing database that captures 92% of prescriptions from U.S. pharmacies. From 2016 to 2022, we found that the rate of surgical opioid prescriptions at the population level declined by 36%, while the average amount of opioids in these prescriptions declined by 46%. As a result of these two changes, the total amount of opioids dispensed to surgical patients declined by 66%.

However, there were two caveats:

First, the decline in surgical opioid prescribing was most rapid before 2020 and has slowed since then.

Second, the average surgical opioid prescription in December 2022 still contained the equivalent of about 44 pills containing 5 milligrams of hydrocodone, far higher than most patients need after surgery.

Acupuncture and Massage May Be Part of Pain Management Plan in Patients with Advanced Cancer

PainRelief.com Interview with:
Jun J. Mao, MD, MSCE
Chief, Integrative Medicine Service
Laurance S. Rockefeller Chair in Integrative Medicine
Memorial Sloan Kettering Cancer Center

PainRelief.com: What is the background for this study?

Response: Most of the pain intervention trials focused on cancer survivors who completed treatment or patients in hospice care, little is know how these treatments work in patients living with advanced cancer. With the improvement in cancer treatment, many people are now living with advanced cancer but suffer from pain from their cancer or treatment.

Since acupuncture and massage have been found effective to manage pain in other populations, we designed this study to compare the effectiveness of these two interventions for musculoskeletal pain among patients living with advanced cancer. We hoped these results will aid patients and their doctors to make informed decision in pain treatment.

Continue reading

Post C-Section Pain Relief: Noninvasive Bioelectronic Device Reduced Need for Opioids

PainRelief.com Interview with:
Jennifer Grasch, MD
Fellow, Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
The Ohio State University Wexner Medical Center

PainRelief.com: What is the background for this study? What are the main findings?

Response: Cesarean delivery is the most commonly performed major surgery in the US. Almost all patients who have a cesarean delivery take opioid pain medications for postoperative pain, but we know that opioids have many short- and long-term side effects.

We conducted a triple-blind sham-controlled randomized clinical trial testing the efficacy of adding transcutaneous treatment with a high-frequency (20,000 Hz) electrical stimulation device to a multimodal analgesic protocol after cesarean delivery. 

Participants who were randomly assigned to the functional device used 47% less opioid medication postoperatively in the hospital and were prescribed fewer opioids at discharge than those who received treatment with a sham device.  

Continue reading

Cannabis-Related Hospitalizations Following Legalization in Canada

PainRelief.com Interview with:
Daniel Myran, MD, MPH, CCFP, FRCPC
Canada Research Chair, Social Accountability, University of Ottawa
Investigator, Bruyère Research Institute 
Assistant Professor, Department of Family Medicine
Lecturer, School of Epidemiology and Public Health
Adjunct Scientist, ICES
University of Ottawa

PainRelief.com: What is the background for this study?

Response: Canada legalized recreational, or non-medical, cannabis in October 2018. Legalization in Canada took a phased approach initially, only the sale of flower-based cannabis products and oils was permitted and there were very few legal cannabis stores and legal sales. Starting in early 2020, Canada allowed the sale of expanded products (e.g. cannabis edibles, vape pens, concentrates), and the number of retail stores began expanding. In this study, we took advantage of this evolution of the legal cannabis market to understand how different phases of legalization were associated with hospitalizations due to cannabis.  

Unequal Access to Chiropractic Pain Relief Care for Back Pain in Patients with Opioid Use Disorder

PainRelief.com Interview with:
Patience Moyo, Ph.D
Assistant Professor of Health Services, Policy and Practice
Center for Gerontology and Healthcare Research
Department of Health Services, Policy, and Practice
Brown University School of Public Health

Patience Moyo, Ph.D
Assistant Professor of Health Services, Policy and Practice
Center for Gerontology and Healthcare Research
Department of Health Services, Policy, and Practice
Brown University School of Public Health

PainRelief.com: What is the background for this study?

Response: Clinical practice guidelines recommend nonpharmacologic treatments as first-line therapies for managing chronic pain. However, little is known about the use of guideline-recommended pain therapies and whether use varies in demographic subgroups. Individuals with co-occurring chronic pain and opioid use disorder deserve particular consideration because of their increased risk of harm from opioids and other pharmacologic therapies combined with their susceptibility to social and structural barriers to accessing health care.

We sought to understand whether the well-established racial and ethnic inequities in pain management extend to individuals with opioid use disorder and to nonpharmacologic pain treatments, specifically physical therapy and chiropractic care.

Continue reading

Cannabis Smoke Exposure is Not Risk Free

PainRelief.com Interview with:
Beth Cohen, MD MAS
Professor of Medicine, UCSF
Co-Director, PRIME Internal Medicine Residency Program
Staff Physician, San Francisco VA Medical Center

PainRelief.com: What is the background for this study?

Response: Though rates of tobacco use are declining, rates of cannabis use are increasing as it becomes more widely legal and available. Though there is not as much research on the long-term health effects of cannabis, cannabis and tobacco smoke contain many of the same carcinogens and toxins and both have particulate matter than is harmful when inhaled.

Continue reading

Study Finds More Than 10 Million New Cases of Adult Chronic Pain Per Year

PainRelief.com Interview with:
Richard L. Nahin, MPH, PhD

National Center for Complementary and Integrative Health
National Institutes of Health, Bethesda, Maryland

PainRelief.com: What is the background for this study?

Response: While there has been extensive research examining the prevalence of chronic pain, far less is known about the incidence of chronic pain.  Understanding the incidence of chronic pain is critical to understanding how such pain manifests and evolves over time.

Continue reading

State Opioid Prescribing Limits Did Little to Reduce Length of Dental Prescriptions

PainRelief.com Interview with:
Kao-Ping Chua, MD, PhD
Susan B. Meister Child Health Evaluation and Research Center
Department of Pediatrics, University of Michigan Medical School
Ann Arbor MI 48109.

Kao-Ping Chua
Dr. Kao-Ping Chua

PainRelief.com: What is the background for this study? What are the main findings?

Response: U.S. dentists account for approximately 11 million opioid prescriptions each year. Excessive opioid prescriptions from dentists can result in leftover opioids that can be diverted or misused. In part to prevent this, most states enacted policies between 2016 and 2018 that restricted the duration of opioid prescriptions for acute pain, such as dental pain.

The objective of this study was to evaluate whether these state opioid prescribing limits were associated with reductions in the duration of opioid prescriptions from dentists. Using national prescription dispensing data from 2014-2020 and a rigorous quasi-experimental study design, we found that this duration did not change after limit enactment. A likely explanation is that most limits allow up to a 7-day supply of opioids, but the typical duration of dental opioid prescriptions during the study period was about a 3-day supply. For this reason, state limits had little ability to reduce this duration in the first place.

University of Pittsburgh Study Finds Durable Pain Relief in Obese Patients Following Bariatric Surgery

PainRelief.com Interview with:
Wendy C. King, PhD
Epidemiology Data Center
School of Public Health
University of Pittsburgh
Pittsburgh, PA

Dr. King

PainRelief.com: What is the background for this study?

Response: Previous studies had provided evidence that bariatric surgical procedures are associated with improvements in pain, physical function and work productivity. However, most prior studies only followed participants 1-2 years, at which point participants were at the peak of their weight loss. 

Among a large cohort of US adults, we wanted to evaluate how much initial improvements in pain, physical function and work productivity declined during long-term follow-up, when some degree of weight regain is not uncommon. We limited our study to adults who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG), the two most common bariatric surgical procedures done today.

Headache: Clinical Trial Finds Oral Atogepant Reduced Monthly Migraine Days

Dr. Trugman

PainRelief.com Interview with:

Joel M. Trugman, MD
Associate Vice President
Neuroscience Development
AbbVie

PainRelief.com:  What is the background for this study?  What are the main findings?

Response: Migraine is a disabling chronic disease characterized by recurrent headache attacks and associated symptoms, including nausea, phonophobia, or sensitivity to sound, and photophobia, or sensitivity to light.

The ADVANCE clinical trial is a phase 3, randomized, double-blind, placebo-controlled trial and examined the safety and efficacy of atogepant, an oral, small-molecule calcitonin gene-related peptide receptor antagonist in patients with episodic migraine. The primary efficacy endpoint was the change from baseline in mean monthly migraine days (MMD) across the 12-week treatment period. This analysis that was recently published examined the efficacy of atogepant using 4 levels of mean monthly migraine day (MMD) responder rates. 

This analysis found that all doses of atogepant significantly increased the proportion of participants who achieved a ≥25%, ≥50%, ≥75% and 100% reduction in mean monthly migraine days over 12 weeks of treatment.